Coleman M A, McCowan L M, Pattison N S, Mitchell M
Departments of Obstetrics and Gynaecology and Pharmacology and Clinical Pharmacology, National Women's Hospital, Auckland, New Zealand.
Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1553-8. doi: 10.1016/s0002-9378(98)70023-7.
The aims of this study were to evaluate a prototype bedside test for fetal fibronectin detection in women with symptoms of preterm labor, to compare the efficacy of obtaining fetal fibronectin swabs with and without a speculum, and to assess the value of combining the fetal fibronectin test with cervical dilatation for predicting delivery within 10 days.
This investigation prospectively studied a cohort of women with symptoms of preterm labor (n = 121), gestational age between 24 and 33 6/7 weeks, and cervical dilatation </=3 cm. Vaginal swabs for fibronectin testing with the bedside dipstick Fetal Fibronectin Membrane Immunoassay test (Adeza Biomedical, Sunnyvale, Calif) were obtained with and without a speculum. Results were not available to the clinicians.
Twenty-two percent of the fetal fibronectin samples collected with a speculum (27/121) yielded positive results. The incidence of delivery within 10 days of testing was 14% (17/121). Fetal fibronectin detection predicted delivery within 10 days with sensitivity, specificity, and positive and negative predictive values of 65%, 85%, 41%, and 94%, respectively. The positive and negative likelihood ratios were 4.3 and 0.41, respectively. There was substantial association between samples obtained with and without a speculum (Cohen kappa statistic 0.65, 95% confidence interval 0.44-0.87). Cervical dilatation >/=1 cm predicted delivery within 10 days with sensitivity, specificity, and positive and negative predictive values of 71%, 87%, 46%, and 95%, respectively, with positive and negative likelihood ratios of 5.5 and 0.33, respectively. Combination of fetal fibronectin testing with cervical dilatation >/=1 cm did not significantly improve the fetal fibronectin test characteristics. After exclusion of women with slight vaginal bleeding, cervical dilatation >/=1 cm and fetal fibronectin status remained the only independent variables associated with delivery within 10 days.
Fetal fibronectin testing according to this prototype may have a limited role in clinical decision analysis. In this study a cervical dilatation >/=1 cm had predictive values equivalent to those of the fetal fibronectin test, and it should be evaluated further in a clinical setting.
本研究旨在评估一种用于检测早产症状女性胎儿纤连蛋白的床旁检测原型,比较使用和不使用窥器获取胎儿纤连蛋白拭子的效果,并评估将胎儿纤连蛋白检测与宫颈扩张相结合对预测10天内分娩的价值。
本调查前瞻性研究了一组有早产症状(n = 121)、孕周在24至33 6/7周之间且宫颈扩张≤3 cm的女性。使用床边试纸法胎儿纤连蛋白膜免疫测定试验(Adeza Biomedical,加利福尼亚州桑尼维尔)进行胎儿纤连蛋白检测的阴道拭子,分别在使用和不使用窥器的情况下获取。临床医生无法得知检测结果。
使用窥器采集的胎儿纤连蛋白样本中有22%(27/121)呈阳性结果。检测后10天内分娩的发生率为14%(17/121)。胎儿纤连蛋白检测对10天内分娩的预测敏感性、特异性、阳性预测值和阴性预测值分别为65%、85%、41%和94%。阳性似然比和阴性似然比分别为4.3和0.41。使用和不使用窥器获取的样本之间存在显著相关性(科恩kappa统计量为0.65,95%置信区间为0.44 - 0.87)。宫颈扩张≥1 cm对10天内分娩的预测敏感性、特异性、阳性预测值和阴性预测值分别为71%、87%、46%和95%,阳性似然比和阴性似然比分别为5.5和0.33。胎儿纤连蛋白检测与宫颈扩张≥1 cm相结合并未显著改善胎儿纤连蛋白检测的特征。排除有轻微阴道出血的女性后,宫颈扩张≥1 cm和胎儿纤连蛋白状态仍然是与10天内分娩相关的唯一独立变量。
根据该原型进行的胎儿纤连蛋白检测在临床决策分析中的作用可能有限。在本研究中,宫颈扩张≥1 cm的预测价值与胎儿纤连蛋白检测相当,应在临床环境中进一步评估。